What Is a CCI Control Strategy?

A CCI control strategy is a structured, pre-defined framework that governs how pharmaceutical manufacturers interpret, investigate, and act upon Container Closure Integrity test (CCIT) results. It exists to prevent two equally dangerous failure modes: overreacting to a single uncharacterized positive result by condemning an entire lot without investigation, and underreacting by dismissing a confirmed integrity breach without adequate corrective action.

Why can't a positive CCI result simply mean batch rejection?

Because a positive result answers a narrow question: a signal requiring classification has occurred. It does not, by itself, answer the lot disposition question. PTI deterministic methods — vacuum decay and HVLD — produce results with 4–6 sigma separation between conforming and nonconforming containers. At 6σ, the false positive rate is approximately 1 in 10,000,000 tested units. That level of measurement precision demands an equally precise response, not a reflexive one.

What are the two failure modes a control strategy prevents?

Overreaction — discarding an entire lot based on a single, uncharacterized positive without scientific investigation — wastes product, disrupts supply, and generates regulatory questions about the quality system's scientific rigor.

Underreaction — dismissing a confirmed integrity breach or continuing production without corrective action — exposes patients to risk and creates the conditions for a far more serious regulatory event downstream.

What does a control strategy actually contain?

A complete control strategy defines: how results are classified by signal magnitude, how the instrument is challenged before any retest occurs, which retest rules apply by technology, how the lot impact is statistically assessed using an expanded sampling plan, what evidence is required before a lot can be released, and what QA gates must be cleared at each stage. All of these rules must exist before a positive result occurs — they cannot be created or interpreted in the middle of a deviation investigation.

Who owns the control strategy?

PTI provides the framework, the classification logic, the statistical sampling tools, and technology-specific guidance. The client owns final batch disposition. No lot release or rejection decision can be delegated to PTI — that authority rests exclusively with the client's Quality Assurance function and must be integrated into their Pharmaceutical Quality System.